SCHEMBL840571

SCHEMBL840571

N#C/C(=C\C=C\c1cccc(Br)n1)C(=O)NCc1ccccc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP9X Q93008 2/20 0.66
MCL1 Q07820 1/20 0.66
MAOB P27338 3/20 0.58
LMNA P02545 4/20 0.57
GAA P10253 1/20 0.57
MITF O75030 1/20 0.56
PLIN1 O60240 1/20 0.52
PLIN5 Q00G26 1/20 0.52
ABHD5 Q8WTS1 1/20 0.52
ALDH1A1 P00352 3/20 0.50
HPGD P15428 3/20 0.50
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
STAT3 P40763 1/20 0.47
GLA P06280 1/20 0.47
UCHL1 P09936 1/20 0.46
USP5 P45974 1/20 0.46
EEF2K O00418 1/20 0.46
PLK4 O00444 1/20 0.46
PIM1 P11309 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL840572 1.00 USP9X (0.66) USP9XMCL1MAOBLMNAGAA
SCHEMBL1934858 0.89 MAOB (0.59) USP9XMCL1MAOBLMNAGAA
SCHEMBL841233 0.87 MCL1 (0.66) USP9XMCL1MAOBLMNAGAA
SCHEMBL841232 0.87 MCL1 (0.66) USP9XMCL1MAOBLMNAGAA
SCHEMBL15947783 0.87 MCL1 (0.66) USP9XMCL1MAOBLMNAGAA
SCHEMBL1315618 0.86 USP9X (0.87) USP9XMCL1LMNAPLIN1PLIN5
SCHEMBL30024196 0.86 USP9X (0.87) USP9XMCL1LMNAPLIN1PLIN5
SCHEMBL1315620 0.86 USP9X (0.87) USP9XMCL1LMNAPLIN1PLIN5
SCHEMBL4485275 0.80 MCL1 (1.00) MCL1MAOBLMNAGAAMITF
SCHEMBL4485269 0.80 MCL1 (1.00) MCL1MAOBLMNAGAAMITF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9000179-B2 Inhibitors of proliferation and activation of signal transducer and activator of transcription (STATs) BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2015-04-07 US disclosed
US-9000179-B2 Inhibitors of proliferation and activation of signal transducer and activator of transcription (STATs) BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2015-04-07 US disclosed
US-9000179-B2 Inhibitors of proliferation and activation of signal transducer and activator of transcription (STATs) BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2015-04-07 US disclosed
EP-2307367-B1 NOVEL INHIBITORS OF PROLIFERATION AND ACTIVATION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION (STATS) UNIV TEXAS (US) 2014-09-24 EP disclosed
EP-2307367-B1 NOVEL INHIBITORS OF PROLIFERATION AND ACTIVATION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION (STATS) UNIV TEXAS (US) 2014-09-24 EP disclosed
US-20140228414-A1 NOVEL INHIBITORS OF PROLIFERATION AND ACTIVATION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION (STATS) BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2014-08-14 US disclosed
US-20140228414-A1 NOVEL INHIBITORS OF PROLIFERATION AND ACTIVATION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION (STATS) BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2014-08-14 US disclosed
US-20140228414-A1 NOVEL INHIBITORS OF PROLIFERATION AND ACTIVATION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION (STATS) BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2014-08-14 US disclosed
US-8637675-B2 Inhibitors of proliferation and activation of signal transducer and activators of transcription (STATS) BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2014-01-28 US disclosed
US-8637675-B2 Inhibitors of proliferation and activation of signal transducer and activators of transcription (STATS) BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2014-01-28 US disclosed
US-20110275577-A1 METHODS OF TREATING DERMATOLOGIC, GYNECOLOGIC, AND GENITAL DISORDERS WITH CAFFEIC ACID ANALOGS MOLECULIN, LLC (US) 2011-11-10 US disclosed
US-20110275577-A1 METHODS OF TREATING DERMATOLOGIC, GYNECOLOGIC, AND GENITAL DISORDERS WITH CAFFEIC ACID ANALOGS MOLECULIN, LLC (US) 2011-11-10 US disclosed
WO-2011069141-A2 INTERFERON THERAPIES IN COMBINATION WITH BLOCKADE OF STAT3 ACTIVATION BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2011-06-09 WO disclosed
WO-2011069141-A2 INTERFERON THERAPIES IN COMBINATION WITH BLOCKADE OF STAT3 ACTIVATION BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2011-06-09 WO disclosed
EP-2307367-A2 NOVEL INHIBITORS OF PROLIFERATION AND ACTIVATION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION (STATS) Board of Regents, The University of Texas System (US) 2011-04-13 EP disclosed
US-20110053992-A1 Novel Inhibitors of Proliferation and Activation of Signal Transducer and Activator of Transcription (STATS) BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2011-03-03 US disclosed
US-20110053992-A1 Novel Inhibitors of Proliferation and Activation of Signal Transducer and Activator of Transcription (STATS) BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2011-03-03 US disclosed
US-20110053992-A1 Novel Inhibitors of Proliferation and Activation of Signal Transducer and Activator of Transcription (STATS) BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2011-03-03 US disclosed
WO-2010005807-A2 NOVEL INHIBITORS OF PROLIFERATION AND ACTIVATION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION (STATS) BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2010-01-14 WO disclosed
WO-2010005807-A2 NOVEL INHIBITORS OF PROLIFERATION AND ACTIVATION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION (STATS) BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2010-01-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110275577-A1 METHODS OF TREATING DERMATOLOGIC, GYNECOLOGIC, AND GENITAL DISORDERS WITH CAFFEIC ACID ANALOGS VHL, PRKDC, POLR1C USP9X 3737/4885MCL1 1703/4885MAOB 3270/4885
US-20110053992-A1 Novel Inhibitors of Proliferation and Activation of Signal Transducer and Activator of Transcription (STATS) STAT5A, STAT3, STAT5B USP9X 2957/4885MCL1 368/4885MAOB 3679/4885
US-20140228414-A1 NOVEL INHIBITORS OF PROLIFERATION AND ACTIVATION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION (STATS) STAT5A, STAT3, STAT5B USP9X 2957/4885MCL1 368/4885MAOB 3679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.